Castle Biosciences 주식 주식분석 | 주식가격 | 뉴스 | CSTL | US14843C1053 | A2PNH3

날짜	Castle Biosciences 주식 가격
	27.53 undefined
	27.85 undefined
	27.01 undefined
	27.96 undefined
	26.99 undefined
	27.14 undefined
	26.97 undefined
	27.69 undefined
	26.75 undefined
	26.83 undefined
	27.84 undefined
	26.81 undefined
	24.90 undefined
	21.85 undefined
	22.28 undefined
	23.04 undefined
	24.13 undefined
	23.73 undefined
	22.03 undefined
	21.06 undefined
	19.31 undefined

날짜	Castle Biosciences 매출	Castle Biosciences EBIT	Castle Biosciences 이익
2029e	384.44 백만 undefined	0 undefined	6.48 백만 undefined
2028e	366.13 백만 undefined	6.12 백만 undefined	8.87 백만 undefined
2027e	331.96 백만 undefined	-13.26 백만 undefined	-6.9 백만 undefined
2026e	303.38 백만 undefined	-39.03 백만 undefined	-31.82 백만 undefined
2025e	266.69 백만 undefined	-60.03 백만 undefined	-53.91 백만 undefined
2024e	265.6 백만 undefined	-53.58 백만 undefined	-45.45 백만 undefined
2023	219.79 백만 undefined	-67.98 백만 undefined	-57.47 백만 undefined
2022	137 백만 undefined	-91.2 백만 undefined	-67.1 백만 undefined
2021	94.1 백만 undefined	-40.1 백만 undefined	-31.3 백만 undefined
2020	62.6 백만 undefined	-6.5 백만 undefined	-10.3 백만 undefined
2019	51.9 백만 undefined	7.3 백만 undefined	3 백만 undefined
2018	22.8 백만 undefined	-3.8 백만 undefined	-10.2 백만 undefined
2017	13.8 백만 undefined	-10.9 백만 undefined	-15.3 백만 undefined

	매출	EBIT	이익
2017	13.8 백만 USD	-10.9 백만 USD	-15.3 백만 USD
2018	22.8 백만 USD	-3.8 백만 USD	-10.2 백만 USD
2019	51.9 백만 USD	7.3 백만 USD	3 백만 USD
2020	62.6 백만 USD	-6.5 백만 USD	-10.3 백만 USD
2021	94.1 백만 USD	-40.1 백만 USD	-31.3 백만 USD
2022	137 백만 USD	-91.2 백만 USD	-67.1 백만 USD
2023	219.79 백만 USD	-67.98 백만 USD	-57.47 백만 USD
2024e	265.6 백만 USD	-53.58 백만 USD	-45.45 백만 USD
2025e	266.69 백만 USD	-60.03 백만 USD	-53.91 백만 USD
2026e	303.38 백만 USD	-39.03 백만 USD	-31.82 백만 USD
2027e	331.96 백만 USD	-13.26 백만 USD	-6.9 백만 USD
2028e	366.13 백만 USD	6.12 백만 USD	8.87 백만 USD
2029e	384.44 백만 USD	0 USD	6.48 백만 USD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
13	22	51	62	94	137	219	265	266	303	331	366	384
-	69.23	131.82	21.57	51.61	45.74	59.85	21.00	0.38	13.91	9.24	10.57	4.92
61.54	77.27	86.27	85.48	82.98	76.64	79.45	-	-	-	-	-	-
8	17	44	53	78	105	174	0	0	0	0	0	0
-10	-3	7	-6	-40	-91	-67	-53	-60	-39	-13	6	0
-76.92	-13.64	13.73	-9.68	-42.55	-66.42	-30.59	-20.00	-22.56	-12.87	-3.93	1.64	-
-15	-10	3	-10	-31	-67	-57	-45	-53	-31	-6	8	6
-	-33.33	-130.00	-433.33	210.00	116.13	-14.93	-21.05	17.78	-41.51	-80.65	-233.33	-25.00
16	16	17.1	18.9	25.1	26.1	26.8	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

1.2	4.5	98.8	409.9	329.6	258.6	243.1
4.7	12.1	14.6	12.8	17.3	23.5	38.3
0	0	0	0	0	0	0
0.3	0.9	1.2	2.2	2	4	7.94
0.5	0.7	2	4.8	4.8	6.2	6.29
6.7	18.2	116.6	429.7	353.7	292.3	295.64
1.5	1.5	2.1	7.1	16.9	26.5	37.74
0	0	0	0	0	0	0
1.6	2.5	0.9	1.1	1.3	1.1	1.19
0	0	0	0	88.9	115.7	106.64
0	0	0	0	0	10.7	10.69
0.1	0.2	0.1	1.5	1.7	1.1	1.44
3.2	4.2	3.1	9.7	108.8	155.1	157.71
9.9	22.4	119.7	439.4	462.5	447.4	453.34

36.1	46.5	0	0	0	0	0.03
0.8	0.9	137.3	478.2	505.5	560.4	609.48
-51.1	-57.5	-52.2	-62.5	-93.8	-160.9	-218.37
0	0	0	0	0	-400	136
0	0	0	0	0	0	0
-14.2	-10.1	85.1	415.7	411.7	399.1	391.27
1.1	1.5	1.9	2.1	2.5	4.7	10.27
3.1	5.3	7.5	12.1	20.6	29.4	33.85
0	0	0.1	6.7	1.7	1.8	3.48
0	0	0	0	0	0	0
1	0	5.8	0	0.1	0.1	0.07
5.2	6.8	15.3	20.9	24.9	36	47.67
17.6	24.5	19.3	0	0.1	0.1	0.03
0	0	0	0	600	400	206
1.3	1.2	0.1	2.8	25.2	11.5	14.17
18.9	25.7	19.4	2.8	25.9	12	14.4
24.1	32.5	34.7	23.7	50.8	48	62.07
9.9	22.4	119.8	439.4	462.5	447.1	453.34

2017	2018	2019	2020	2021	2022	2023
-12	-6	5	-10	-31	-67	-57
0	0	0	0	3	10	12
0	0	0	0	-8	-1	0
0	-7	0	9	-4	0	-6
0	1	2	18	43	53	97
1	1	2	1	0	0	0
0	0	0	0	0	0	0
-12	-12	7	9	-18	-41	-5
0	0	0	-4	-3	-5	-13
0	0	0	-4	-66	-166	-16
0	0	0	0	-63	-160	-2
0	0	0	0	0	0	0
8	5	20	-27	0	0	0
0	10	67	331	4	0	0
8	15	88	305	5	1	-2
0	0	0	1,000	1,000	0	-2,000
0	0	0	0	0	0	0
-3	3	94	311	-80	-206	-24
-12.72	-12.57	6.08	5.12	-22.46	-47.29	-19.25
0	0	0	0	0	0	0

Castle Biosciences 브루토마진	Castle Biosciences 이익 마진	Castle Biosciences EBIT-마진	Castle Biosciences 이익 마진
2029e	79.53 %	0 %	1.68 %
2028e	79.53 %	1.67 %	2.42 %
2027e	79.53 %	-3.99 %	-2.08 %
2026e	79.53 %	-12.87 %	-10.49 %
2025e	79.53 %	-22.51 %	-20.22 %
2024e	79.53 %	-20.17 %	-17.11 %
2023	79.53 %	-30.93 %	-26.15 %
2022	76.64 %	-66.57 %	-48.98 %
2021	83.21 %	-42.61 %	-33.26 %
2020	84.66 %	-10.38 %	-16.45 %
2019	85.93 %	14.07 %	5.78 %
2018	76.75 %	-16.67 %	-44.74 %
2017	63.77 %	-78.99 %	-110.87 %

	브루토마진	EBIT-마진	이익 마진
2017	63.77 %	-78.99 %	-110.87 %
2018	76.75 %	-16.67 %	-44.74 %
2019	85.93 %	14.07 %	5.78 %
2020	84.66 %	-10.38 %	-16.45 %
2021	83.21 %	-42.61 %	-33.26 %
2022	76.64 %	-66.57 %	-48.98 %
2023	79.53 %	-30.93 %	-26.15 %
2024e	79.53 %	-20.17 %	-17.11 %
2025e	79.53 %	-22.51 %	-20.22 %
2026e	79.53 %	-12.87 %	-10.49 %
2027e	79.53 %	-3.99 %	-2.08 %
2028e	79.53 %	1.67 %	2.42 %
2029e	79.53 %	0 %	1.68 %

날짜	Castle Biosciences 주당 매출	Castle Biosciences EBIT 당 주식	Castle Biosciences 주당 이익
2029e	13.92 undefined	0 undefined	0.23 undefined
2028e	13.26 undefined	0 undefined	0.32 undefined
2027e	12.02 undefined	0 undefined	-0.25 undefined
2026e	10.99 undefined	0 undefined	-1.15 undefined
2025e	9.66 undefined	0 undefined	-1.95 undefined
2024e	9.62 undefined	0 undefined	-1.65 undefined
2023	8.2 undefined	-2.54 undefined	-2.14 undefined
2022	5.25 undefined	-3.49 undefined	-2.57 undefined
2021	3.75 undefined	-1.6 undefined	-1.25 undefined
2020	3.31 undefined	-0.34 undefined	-0.54 undefined
2019	3.04 undefined	0.43 undefined	0.18 undefined
2018	1.43 undefined	-0.24 undefined	-0.64 undefined
2017	0.86 undefined	-0.68 undefined	-0.96 undefined

	주당 매출	EBIT 당 주식	주당 이익
2017	0.86 USD	-0.68 USD	-0.96 USD
2018	1.43 USD	-0.24 USD	-0.64 USD
2019	3.04 USD	0.43 USD	0.18 USD
2020	3.31 USD	-0.34 USD	-0.54 USD
2021	3.75 USD	-1.6 USD	-1.25 USD
2022	5.25 USD	-3.49 USD	-2.57 USD
2023	8.2 USD	-2.54 USD	-2.14 USD
2024e	9.62 USD	0 USD	-1.65 USD
2025e	9.66 USD	0 USD	-1.95 USD
2026e	10.99 USD	0 USD	-1.15 USD
2027e	12.02 USD	0 USD	-0.25 USD
2028e	13.26 USD	0 USD	0.32 USD
2029e	13.92 USD	0 USD	0.23 USD

	주식 수량
2017	16 백만 Aktien
2018	16 백만 Aktien
2019	17.1 백만 Aktien
2020	18.9 백만 Aktien
2021	25.1 백만 Aktien
2022	26.1 백만 Aktien
2023	26.8 백만 Aktien
2024e	26.8 백만 Aktien
2025e	26.8 백만 Aktien
2026e	26.8 백만 Aktien
2027e	26.8 백만 Aktien
2028e	26.8 백만 Aktien
2029e	26.8 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.27	0.31 (213.14 %)	2024 Q2
-0.34	-0.09 (73.4 %)	2024 Q1
-0.55	-0.1 (81.72 %)	2023 Q4
-0.78	-0.26 (66.62 %)	2023 Q3
-0.93	-0.7 (25 %)	2023 Q2
-0.91	-1.1 (-21 %)	2023 Q1
-0.85	-0.78 (8.7 %)	2022 Q4
-0.9	-0.77 (14.22 %)	2022 Q3
-0.78	-0.06 (92.28 %)	2022 Q2
-0.72	-0.97 (-34.48 %)	2022 Q1
-0.48	-0.25 (47.85 %)	2021 Q4
-0.41	-0.47 (-13.77 %)	2021 Q3
-0.37	-0.34 (8.92 %)	2021 Q2
-0.24	-0.17 (29.08 %)	2021 Q1
-0.12	-0.17 (-36.66 %)	2020 Q4
-0.12	-0.23 (-96.08 %)	2020 Q3
-0.41	-0.19 (53.14 %)	2020 Q2
-0.15	0.03 (119.93 %)	2020 Q1
-0.21	0.11 (153.04 %)	2019 Q4
-0.31	0.05 (116.07 %)	2019 Q3
-1.38	-1.05 (24.17 %)	2019 Q2

%-지분	이름	주식	변경
9.24 %	Wasatch Global Investors Inc	2,551,088	-39,863
7.85 %	Granahan Investment Management, LLC	2,166,471	-321,202
7.08 %	BlackRock Institutional Trust Company, N.A.	1,954,358	119,573
5.74 %	Principal Global Investors (Equity)	1,585,673	103,503
5.27 %	The Vanguard Group, Inc.	1,456,359	22,093
4.46 %	Bellevue Asset Management AG	1,232,378	4,347
3.50 %	Deerfield Management Company, L.P.	965,428	18,808
3.12 %	Victory Capital Management Inc.	861,234	-114,376
2.64 %	Portolan Capital Management, L.L.C.	728,653	475,625
2.59 %	Millennium Management LLC	716,350	121,254
2.40 %	Dimensional Fund Advisors, L.P.	663,882	108,481
2.10 %	State Street Global Advisors (US)	579,918	14,754
2.05 %	Geode Capital Management, L.L.C.	566,115	29,879
2.01 %	Jacobs Levy Equity Management, Inc.	553,860	-11,131
1.97 %	Kornitzer Capital Management Inc.	542,874	-105,350
1.95 %	Palisade Capital Management, LLC	539,135	-63,126
1.59 %	Morgan Stanley & Co. LLC	439,907	411,346
1.53 %	Maetzold (Derek J)	422,221	-4,315
1.29 %	Parkman Healthcare Partners LLC	357,156	132,564
1.19 %	Citadel Advisors LLC	328,749	-189,309
1.18 %	Intrinsic Edge Capital Management, LLC	326,270	170,000
1.01 %	Columbia Threadneedle Investments (US)	279,727	13,727
0.86 %	New York State Common Retirement Fund	237,126	-8,742
0.79 %	Northern Trust Investments, Inc.	218,429	12,045
0.77 %	Next Century Growth Investors, LLC	213,886	213,886
0.75 %	Charles Schwab Investment Management, Inc.	207,295	6,306
0.66 %	Banque Pictet & Cie S.A.	182,664	-20,611
0.66 %	Nuveen LLC	181,948	5,664
0.62 %	Invenomic Capital Management LP	171,812	-114,145
0.62 %	Monarch Partners Asset Management LLC	170,195	-18,436
0.60 %	Trustcore Financial Services, LLC	164,897	146
0.58 %	Schonfeld Strategic Advisors LLC	161,300	13,270
0.56 %	DWS Investments UK Limited	154,592	141,633
0.55 %	Oelschlager (Kristen M)	151,411	1,536
0.50 %	BofA Global Research (US)	138,578	117,754
0.47 %	Algert Global LLC	129,110	61,898
0.44 %	Advisors Capital Management, LLC	121,889	4,999
0.43 %	BlackRock Advisors (UK) Limited	118,513	2,428
0.41 %	Renaissance Technologies LLC	112,400	5,600
0.39 %	BlackRock Financial Management, Inc.	107,769	36,844
0.38 %	Knights of Columbus	106,262	52,921
0.37 %	BlackRock Asset Management Ireland Limited	101,860	-5,225
0.37 %	BioBrit LLC	101,731	-243,393
0.36 %	Ohio Public Employees Retirement System	100,254	0
0.34 %	TritonPoint Wealth, LLC	94,356	94,356
0.33 %	Acadian Asset Management LLC	91,381	91,381
0.32 %	Connor, Clark & Lunn Investment Management Ltd.	88,570	7,985
0.31 %	IST Investmentstiftung	86,057	7
0.29 %	Millrace Asset Group, Inc.	78,914	1,599
0.27 %	BNY Mellon Asset Management	74,304	12,188
0.25 %	Cubist Systematic Strategies, LLC	70,216	-66,321
0.25 %	Orion Portfolio Solutions, LLC	69,733	-4,294
0.25 %	BlackRock Investment Management, LLC	68,458	-1,202
0.21 %	Ally Bridge Group (HK) Limited	59,250	5,032
0.21 %	Conestoga Capital Advisors, LLC	57,848	0
0.19 %	Polar Asset Management Partners Inc.	53,200	53,200
0.19 %	D. E. Shaw & Co., L.P.	52,364	52,364
0.18 %	Juvenal (Tobin W)	50,359	1,272
0.18 %	Schweizerische Nationalbank	50,200	-5,000
0.18 %	Envestnet Asset Management, Inc.	50,027	-3,956
0.18 %	Two Sigma Investments, LP	49,400	-19,900
0.17 %	GSA Capital Partners LLP	48,096	-4,099
0.16 %	Marshall Wace LLP	44,900	44,900
0.16 %	Dimensional Fund Advisors, Ltd.	44,723	2,409
0.16 %	AllianceBernstein L.P.	44,690	0
0.16 %	Numerai Gp LLC	43,979	-24,184
0.16 %	Stephens Capital Management	43,579	-53,372
0.16 %	Jane Street Capital, L.L.C.	43,351	22,560
0.15 %	Goldman Sachs Asset Management, L.P.	42,533	-14,256
0.15 %	UBS Financial Services, Inc.	41,477	23,436
0.15 %	Stokes (Frank)	40,823	1,272
0.15 %	Neo Investimentos	40,423	40,423
0.14 %	Barclays Bank PLC	39,168	30,186
0.14 %	CAPTRUST Financial Advisors	38,409	-324
0.14 %	Rhumbline Advisers Ltd. Partnership	37,908	60
0.14 %	Goldman Sachs & Company, Inc.	37,856	-57,106
0.13 %	Aspinall (Mara G)	35,503	0
0.12 %	Credit Suisse Funds AG	34,050	4,598
0.12 %	Avantis Investors	33,523	11,211
0.12 %	Brinker Capital Investments, LLC	32,824	-3,636
0.12 %	Abaris Investment Management AG	32,500	5,000
0.12 %	Perkins Capital Management, Inc.	32,140	2,980
0.11 %	Royce Investment Partners	31,642	8,833
0.11 %	Engineers Gate Manager, L.P.	31,267	31,267
0.11 %	Simon Quick Advisors, LLC	29,062	0
0.10 %	Morgan Stanley Investment Management Inc. (US)	27,932	27,374
0.10 %	Northern Trust Global Investments	27,379	-2,213
0.10 %	Parallel Advisors, LLC	26,968	0
0.10 %	California State Teachers Retirement System	26,766	-1,112
0.10 %	Boston Advisors, LLC	26,716	0
0.10 %	American Century Investment Management, Inc.	26,709	9,078
0.10 %	Susquehanna International Group, LLP	26,600	26,600
0.09 %	Soleus Capital Management, L.P.	26,000	-257,500
0.09 %	Putnam Investment Management, L.L.C.	25,006	-789
0.09 %	Legal & General Investment Management Ltd.	24,821	4,457
0.09 %	The Norden Group, LLC	24,673	24,673
0.09 %	BlackRock Investment Management (UK) Ltd.	24,663	2,649
0.09 %	State Teachers Retirement System of Ohio	24,100	-4,000
0.09 %	Invesco Capital Management LLC	23,504	-4,514
0.08 %	Townsquare Capital, LLC	22,741	-3,242

What values and corporate philosophy does Castle Biosciences represent?

Castle Biosciences Inc represents values such as innovation, accuracy, and patient-centricity. With a strong corporate philosophy centered around precision medicine, the company utilizes advanced genomic technology to provide actionable, personalized information to aid healthcare decisions for patients with underserved cancers. Castle Biosciences Inc is committed to improving patient outcomes through its proprietary diagnostic tests that offer valuable insights into the individual biology of each patient. By combining science, research, and a patient-first approach, Castle Biosciences Inc strives to empower healthcare providers and patients with the necessary tools to make informed, targeted treatment decisions.

In which countries and regions is Castle Biosciences primarily present?

Castle Biosciences Inc is primarily present in the United States.

What significant milestones has the company Castle Biosciences achieved?

Castle Biosciences Inc has achieved several significant milestones since its inception. The company pioneered the development of DecisionDx®-Melanoma, a groundbreaking gene expression profile test, which has revolutionized the management of melanoma patients. Castle Biosciences Inc has also expanded its product portfolio with DecisionDx®-UM, a test for uveal melanoma, providing accurate prognostic information for physicians and patients. In addition, the company has received numerous awards and recognitions for its innovative approach to personalized medicine, further establishing its leadership in the field. Castle Biosciences Inc continues to drive advancements in genomic diagnostics, improving patient outcomes and transforming cancer care.

What is the history and background of the company Castle Biosciences?

Castle Biosciences Inc is a leading precision oncology company that specializes in molecular diagnostics. Established in 2008, the company is dedicated to providing personalized medicine solutions for patients with challenging cancers. With a focus on dermatologic cancers, Castle Biosciences utilizes advanced genomic and proteomic technology to develop innovative diagnostic tests. Their flagship product, DecisionDx-Melanoma, is a powerful tool that assesses the risk and prognosis of melanoma patients. Castle Biosciences Inc has a strong commitment to research, collaboration, and improving patient outcomes. With their cutting-edge technology and expertise, the company continues to revolutionize cancer diagnostics and treatment strategies.

Who are the main competitors of Castle Biosciences in the market?

The main competitors of Castle Biosciences Inc in the market are Myriad Genetics, Genomic Health, and NanoString Technologies.

In which industries is Castle Biosciences primarily active?

Castle Biosciences Inc is primarily active in the healthcare industry, specifically in the field of precision medicine. The company specializes in developing and commercializing molecular diagnostics tests that provide personalized genomic information to aid in the diagnosis and treatment of various types of cancer. Castle Biosciences Inc's innovative solutions help healthcare professionals make informed decisions about patient care by assessing the likelihood of disease recurrence and determining optimal treatment plans. With a focus on improving patient outcomes, Castle Biosciences Inc is dedicated to advancing precision medicine in oncology.

What is the business model of Castle Biosciences?

The business model of Castle Biosciences Inc revolves around providing diagnostic and prognostic solutions for patients with skin and other cancers. By leveraging advanced genomic technology, the company offers diagnostic tests that assess the risk, recurrence, and progression of various cancers. Castle Biosciences focuses on developing and commercializing molecular diagnostic tests that aid in personalized treatment decisions for cancer patients. With a patient-centric approach, the company aims to improve patient outcomes and contribute to the advancement of precision medicine. Castle Biosciences Inc is dedicated to revolutionizing cancer management through innovative diagnostics.

Castle Biosciences 2024의 P/E 비율은 얼마입니까?

Castle Biosciences의 P/E 비율은 -16.24입니다.

Castle Biosciences 2024의 KUV는 얼마입니까?

Castle Biosciences의 P/S 비율은 2.78입니다.

Castle Biosciences의 AlleAktien 품질 점수는 얼마인가요?

Castle Biosciences에 대한 AlleAktien 품질 점수는 4/10입니다.

Castle Biosciences 2024의 매출은 얼마인가요?

예상되는 Castle Biosciences 매출은 265.6 백만 USD입니다.

Castle Biosciences 2024의 이익은 얼마인가요?

예상되는 Castle Biosciences 이익은 -45.45 백만 USD입니다.

Castle Biosciences은 무엇을 하나요?

Castle Biosciences Inc is a biotechnology company that develops and distributes diagnostic tests and genetic analyses. The company is headquartered in Friendswood, Texas, USA and has been operating in the industry since 2007. The main task of Castle Biosciences is to develop clinically accurate prediction tools to assess the progression of tumors and consider them in patient treatment. For this purpose, the company has developed a range of test procedures based on a combination of genotyping, proteomics, and immuno-sensing methods. The key product of Castle Biosciences is the Prognostic Test, which provides an accurate assessment of the risk of skin cancer. The test uses molecular markers to predict the risk of melanoma or ocular melanoma and determine if therapy is necessary. Another product is DecisionDx-UM, a powerful diagnostic assay that aids in the prognosis of malignant uveal melanoma (UM). In combination with standardized clinical factors such as age, gender, and tumor size, DecisionDx-UM is an important indicator of disease progression as well as promising treatment approaches. Castle Biosciences offers a wide range of proteomic analyses tailored to the needs of the patient. These tests are used to estimate the risk of cancer and enable treating physicians to develop treatment and follow-up strategies. The company also conducts a number of research and development initiatives aimed at understanding the molecular basis of cancer and developing novel diagnostic tests and therapies. The goal is to make groundbreaking scientific discoveries to identify new and improved molecular markers that can be used to assess disease progression and the efficacy of therapies. Overall, Castle Biosciences provides an advanced and accurate platform for cancer diagnostics that can help patients and doctors make better-informed decisions. The company is dedicated to further exploring the molecular basis of cancer and developing more innovative diagnostic tools to improve patient care worldwide. In summary, the business model of Castle Biosciences is focused on the development and marketing of diagnostic tools for cancer treatment. The company offers a wide range of molecular, proteomic, and immuno-sensing analyses that enable accurate prognosis of tumor progression. The company also conducts extensive research and development initiatives to discover new molecular markers for the diagnosis and treatment of cancer.

Castle Biosciences 배당금은 얼마입니까?

Castle Biosciences은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Castle Biosciences이 얼마나 자주 배당을 지급하나요?

Castle Biosciences의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Castle Biosciences ISIN이 무엇입니까?

Castle Biosciences의 ISIN은 US14843C1053입니다.

Castle Biosciences WKN은 무엇인가요?

Castle Biosciences의 WKN은 A2PNH3입니다.

Castle Biosciences 티커는 무엇인가요?

Castle Biosciences의 티커는 CSTL입니다.

Castle Biosciences이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Castle Biosciences은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Castle Biosciences은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Castle Biosciences의 배당 수익률은 얼마입니까?

Castle Biosciences의 현재 배당 수익률은 입니다.

Castle Biosciences의 배당금은 언제 지급되나요?

Castle Biosciences은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Castle Biosciences의 배당금은 얼마나 안전한가요?

Castle Biosciences은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Castle Biosciences의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Castle Biosciences이(가) 속해 있는 섹터는 어디인가요?

Castle Biosciences은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Castle Biosciences kaufen, um die vorherige Dividende zu erhalten?

Castle Biosciences의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Castle Biosciences의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Castle Biosciences의 2023년도 배당금은 얼마였습니까?

2023년에 Castle Biosciences는 0 USD를 배당금으로 지급했습니다.

Castle Biosciences는 어떤 화폐로 배당금을 지급하나요?

Castle Biosciences의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	—
스코프 2 - 구매한 에너지로부터의 간접적인 배출	—
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	—
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	❌
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	65.7
관리 직위에서의 여성 비율	—
아시아 직원 비율	7.2
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	11.6
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	2.9
블랙 매니지먼트 지분	—
흰색 종업원의 비율	74.2
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	✅
개인정보 보호 정책	—
작업 및 건강 보호	✅
카톨릭	✅

환경 보고	✅
이해관계자 참여	❌
콜백 정책	❌
카르텔법	❌

Castle Biosciences 티커	Castle Biosciences FIGI
CSTL:US	BBG006YWVSR3
CSTL:UA	BBG00PKS73F0
CSTL:UC	BBG00PKS73G9
CSTL:UN	BBG00PKS73J6
CSTL:UP	BBG00PKS73K4
CSTL:UQ	BBG00PKS73L3
CSTL:UB	BBG00PKS73M2
CSTL:UM	BBG00PKS73P9
CSTL:UX	BBG00PKS73Q8
CSTL:UD	BBG00PKS73W1
CSTL:UF	BBG00PKS73Z8
CSTL:VY	BBG00PKS7404
CSTL:VJ	BBG00PKS7413
CSTL:VK	BBG00PKS7422
CSTL:VF	BBG00PKS7431
CSTL:VG	BBG00X1P5DN1
CSTL:VP	BBG00X1SLSZ1
CSTLGBX:EO	BBG01KJPKH53
CSTLGBX:X2	BBG01KJPKH62
CSTLGBX:XH	BBG01KJPKH80
CSTLGBX:XF	BBG01KJPKHB6
CSTLGBX:XE	BBG01KJPKHD4
CSTLGBX:XJ	BBG01KJPKHF2
CSTLGBX:XL	BBG01KJPKHG1
CSTLGBX:XG	BBG01KJPKHH0
CSTLGBX:XO	BBG01KJPKHJ8
CSTLGBX:XA	BBG01KJPKHP1
CSTLGBX:E1	BBG01KJPKHR9
CSTLGBX:XT	BBG01KJPKHS8
CSTLGBX:XW	BBG01KJPKHV4
CSTLGBX:XU	BBG01KJPKHW3
CSTLGBX:XY	BBG01KJPKHY1
CSTLGBX:XV	BBG01KJPKHZ0
CSTLGBX:XM	BBG01KJPKJ13
CSTLGBX:XQ	BBG01KJPKJ31
CSTLGBX:XX	BBG01KJPKJ59
CSTLGBX:XZ	BBG01KJPKJ68
CSTLGBX:X1	BBG01KJPKJ95
CSTLGBX:EU	BBG01KJPKK65

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커CSTL

ISINUS14843C1053

WKNA2PNH3

Castle Biosciences 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Castle Biosciences 주가 이력

Castle Biosciences 주식 매출, EBIT, 이익 US14843C1053 · A2PNH3

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Castle Biosciences 매출, 이익 및 EBIT 역사

Castle Biosciences 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Castle Biosciences 주식 마진 US14843C1053 · A2PNH3

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Castle Biosciences 마진 역사

Castle Biosciences 주식 매출, EBIT, 주당 순이익 US14843C1053 · A2PNH3

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Castle Biosciences 매출, 이익 및 EBIT 주당 역사

Castle Biosciences 주식 및 주식 분석

Castle Biosciences Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Castle Biosciences 역사적인 P/E, EBIT 및 P/S에 따른 평가

Castle Biosciences 주식 수량 US14843C1053 · A2PNH3

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Castle Biosciences 수익 예상

Castle Biosciences 수익 놀라움

Eulerpool ESG Scorecard© Castle Biosciences 주식을 위해

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

Castle Biosciences 주식 주주 구조

Castle Biosciences 임원진 및 경영진

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
CSTL

ISIN
US14843C1053

WKN
A2PNH3